Shopping Cart
- Remove All
Your shopping cart is currently empty
T-900607
🥰Excellent
Catalog No. T68147Cas No. 261944-52-9
T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
T-900607
🥰Excellent
Purity: 98.84%
Catalog No. T68147Cas No. 261944-52-9
T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $82 | In Stock | |
| 5 mg | $181 | In Stock | |
| 10 mg | $267 | In Stock | |
| 25 mg | $413 | In Stock | |
| 50 mg | $571 | In Stock | |
| 100 mg | $763 | In Stock | |
| 200 mg | $1,030 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
View MoreBatch Information
Select Batch
Purity:98.84%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic. |
| Targets&IC50 | HeLa cells:< 5 μM, MCF-7/ADR cells:< 5 μM |
| In vitro | t-900607 (compound 5 or VI) showed total growth inhibition for HeLa and MCF-7/ADR cells at<5 μM.[2] |
| In vivo | t-900607 (15 to 270 mg/m; administered intravenously; advanced and/or metastatic solid malignancies patients; over 30 minutes every 21 days) no DLTs were seen until 270 mg/m, the sixth dose level. The dose was decreased to 180 mg/m with increased cardiac monitoring and at this dose 3/4 of patients experienced cardiac toxicity. The study was reopened at 130 mg/m of 6 enrolled patients, 1 had grade 3 drug-related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported on 7/20. The recommended phase II dose for t-900607 is 130 mg/m given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.[1] |
| Molecular Weight | 411.3 |
| Formula | C14H10F5N3O4S |
| Cas No. | 261944-52-9 |
| Smiles | N(S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F)C2=CC(NC(N)=O)=C(OC)C=C2 |
| Color | White |
| Appearance | Solid |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.11 mg/mL (10 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy T-900607 | purchase T-900607 | T-900607 cost | order T-900607 | T-900607 chemical structure | T-900607 in vivo | T-900607 in vitro | T-900607 formula | T-900607 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.